The committee’s role is to develop and maintain AMCP’s bylaws, organizational policies, procedures, and structure consistent with the AMCP mission.
The Educational Affairs Committee role is to ensure that AMCP education programs are highly relevant and valuable to members.
The committee's role is to effectively advocate AMCP’s position relative to current and anticipated state and federal legislative and regulatory issues consistent with the AMCP mission.
The committee's role is to guide the continued development, training, and advocacy of the AMCP Format for Formulary Submissions, including related materials and revisions.
The committee’s role is to identify developments at the state & federal levels regarding managed care pharmacy and to develop strategies regarding consistent with the AMCP mission.
The committee’s role is to oversee strategies consistent with the mission of the Academy in order to maintain a viable and growing membership.
June 2019 News & Views: Educational Affairs Committee Plans Nexus 2019; Cathy Carroll Fund Now Receiving Donations; Cantrell Quoted in Washington Post; AMCP Releases Concepts for Effective PA Practices
The Joint Research Committee encourages the creation and dissemination of relevant research and initiatives to advance patient care services in managed care pharmacy.
May 2019 News & Views: Survey Identifies Barriers and Solutions to Biosimilar Adoption; In Memoriam: Past President Cathy Carroll; CEO Blog: PAs Play Key Role in Appropriate Medication Use; PGY1 Residents First to Rotate at AMCP/Foundation Headquarters
From April 2019 News & Views: James Kenney took the helm as 2019-2020 AMCP President at the Annual Meeting last week in San Diego. The following is a lightly edited version of his inaugural address at the General Session.
From April 2019 News & Views: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies. But formidable barriers, including concerns about safety and efficacy among prescribers and state laws on substitution and interchangeability, have hindered biosimilar adoption.
